GLP1R and type 2 diabetes mellitus: This paracrine effect could not be detected in isolated normal human islets (110); nonetheless, this mechanism may be clinically relevant in the treatment of T2D, as experiments in human islets showed that the GLP-1R agonist liraglutide enhanced somatostatin secretion to reduce hyperglucagonemia induced by the SGLT2 inhibitor dapagliflozin (118).